Aye Y, Li M, Long M J C, Weiss R S (2015) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene, 34(16): 2011-2021. https://doi.org/10.1038/onc.2014.155
Baker C H, Banzon J, Bollinger J M, Stubbe J, Samano V, Robins M J, Lippert B, Jarvi E, Resvick R (1991) 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. Journal of medicinal chemistry, 34(6): 1879-1884.
Blanchard J M (2000) Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues. Biochemical Pharmacology, 60(8): 1179-1184.
Bothou C, Sharma A, Oo A, Kim B, Perge P, Igaz P, Ronchi C L, Shapiro I, Hantel C (2021) Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. Cancers, 13(16). https://doi.org/10.3390/cancers13164200
Brooks T, Wayne J, Massey A J (2021) Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells. DNA repair, 101: 103099. https://doi.org/10.1016/j.dnarep.2021.103099
Caldecott K W (2008) Single-strand break repair and genetic disease. Nature Reviews. Genetics, 9(8): 619-631. https://doi.org/10.1038/nrg2380
Calvo E, Chen V J, Marshall M, Ohnmacht U, Hynes S M, Kumm E, Diaz H B, Barnard D, Merzoug F F, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin A B, Dickgreber N, Wehler T, Sebastian M (2014) Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Investigational New Drugs, 32(5): 955-968. https://doi.org/10.1007/s10637-014-0114-5
Cao M, Chen W (2019) Epidemiology of lung cancer in China. Thoracic cancer, 10(1): 3-7. https://doi.org/10.1111/1759-7714.12916
Carrassa L, Damia G (2017) DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. Cancer treatment reviews, 60: 139-151. https://doi.org/10.1016/j.ctrv.2017.08.013
Dalton S (2015) Linking the Cell Cycle to Cell Fate Decisions. Trends in cell biology, 25(10): 592-600. https://doi.org/10.1016/j.tcb.2015.07.007
Drápela S, Khirsariya P, Van Weerden W M, Fedr R, Suchánková T, Búzová D, Červený J, Hampl A, Puhr M, Watson W R, Culig Z, Krejčí L, Paruch K, Souček K (2020) The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology, 14(10): 2487-2503. https://doi.org/10.1002/1878-0261.12756
Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, Gande S, Stripay J, Ancliffe M, Howlett M, Schoep T, George C, Andradas C, Dyer P, Schluck M, Patterson B, Tacheva-Gigorova S K, Cooper M N, Robinson G, Stewart C, Pfister S M, Kool M, Milde T, Gajjar A, Johns T, Wechsler-Reya R J, Roussel M F, Gottardo N G (2021) Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 13(577). https://doi.org/10.1126/scitranslmed.aba7401
Ewald B, Sampath D, Plunkett W (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Molecular Cancer Therapeutics, 6(4): 1239-1248.
Fan Z, Luo H, Zhou J, Wang F, Zhang W, Wang J, Li S, Lai Q, Xu Y, Wang G, Liang A, Xu J (2020) Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair. Oncology reports, 44(5): 2152-2164. https://doi.org/10.3892/or.2020.7757
Gil Del Alcazar C R, Todorova P K, Habib A A, Mukherjee B, Burma S (2016) Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Molecular Cancer Research : MCR, 14(10): 928-940.
Gorski J W, Ueland F R, Kolesar J M (2020) CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. Diagnostics (Basel, Switzerland), 10(5). https://doi.org/10.3390/diagnostics10050279
Goto H, Natsume T, Kanemaki M T, Kaito A, Wang S, Gabazza E C, Inagaki M, Mizoguchi A (2019) Chk1-mediated Cdc25A degradation as a critical mechanism for normal cell cycle progression. Journal of cell science, 132(2). https://doi.org/10.1242/jcs.223123
Gridelli C, Rossi A, Carbone D P, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R (2015) Non-small-cell lung cancer. Nature reviews. Disease primers, 1: 15009. https://doi.org/10.1038/nrdp.2015.9
Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, Liang Y, Zhang R, Pan J, Zeng Y-X, Kang T (2012) CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. The Journal of Clinical Investigation, 122(6): 2165-2175. https://doi.org/10.1172/JCI61380
Hsu W-H, Zhao X, Zhu J, Kim I-K, Rao G, Mccutcheon J, Hsu S-T, Teicher B, Kallakury B, Dowlati A, Zhang Y-W, Giaccone G (2019) Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14(6): 1032-1045. https://doi.org/10.1016/j.jtho.2019.01.028
Huff S E, Winter J M, Dealwis C G (2022) Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 12(6). https://doi.org/10.3390/biom12060815
Isono M, Okubo K, Asano T, Sato A (2021) Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells. Scientific reports, 11(1): 10181. https://doi.org/10.1038/s41598-021-89684-5
Jin C-Y, Du L, Nuerlan A H, Wang X-L, Yang Y-W, Guo R (2020) High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging, 13(3): 3518-3535. https://doi.org/10.18632/aging.202292
Jones R M, Kotsantis P, Stewart G S, Groth P, Petermann E (2014) BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine. Molecular Cancer Therapeutics, 13(10): 2412-2421. https://doi.org/10.1158/1535-7163.MCT-13-0862
Kar S (2016) Unraveling Cell-Cycle Dynamics in Cancer. Cell systems, 2(1). https://doi.org/10.1016/j.cels.2016.01.007
Kastan M B, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature, 432(7015): 316-323.
Li X-Q, Ren J, Chen P, Chen Y-J, Wu M, Wu Y, Chen K, Li J (2018) Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair. Acta Pharmacologica Sinica, 39(8): 1359-1372. https://doi.org/10.1038/aps.2017.187
Li Y, Wang L R, Chen J, Lou Y, Zhang G B (2014) First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. Disease Markers, 2014: 960458. https://doi.org/10.1155/2014/960458
Liang A-L, Du S-L, Zhang B, Zhang J, Ma X, Wu C-Y, Liu Y-J (2019) Screening miRNAs associated with resistance gemcitabine from exosomes in A549 lung cancer cells. Cancer Management and Research, 11: 6311-6321. https://doi.org/10.2147/CMAR.S209149
Liang M, Zhao T, Ma L, Guo Y (2018) CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. Oncology reports, 39(3): 1322-1330. https://doi.org/10.3892/or.2017.6168
Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G (2008) Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Research : BCR, 10(5): R81. https://doi.org/10.1186/bcr2150
Mcguire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances In Nutrition (Bethesda, Md.), 7(2): 418-419. https://doi.org/10.3945/an.116.012211
Meyer F, Becker S, Classen S, Parplys A C, Mansour W Y, Riepen B, Timm S, Ruebe C, Jasin M, Wikman H, Petersen C, Rothkamm K, Borgmann K (2020) Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer. Cells, 9(1). https://doi.org/10.3390/cells9010238
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Annals of oncology : official journal of the European Society for Medical Oncology, 17 Suppl 5: v7-12.
Moeglin E, Desplancq D, Conic S, Oulad-Abdelghani M, Stoessel A, Chiper M, Vigneron M, Didier P, Tora L, Weiss E (2019) Uniform Widespread Nuclear Phosphorylation of Histone H2AX Is an Indicator of Lethal DNA Replication Stress. Cancers, 11(3). https://doi.org/10.3390/cancers11030355
Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A (2013) Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC cancer, 13: 604. https://doi.org/10.1186/1471-2407-13-604
Morimoto Y, Takada K, Takeuchi O, Takagi A, Watanabe K, Hirohara M, Hamamoto T, Masuda Y (2020) Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. Oncology reports, 43(2): 689-699. https://doi.org/10.3892/or.2019.7421
Nawaz K, Webster R M (2016) The non-small-cell lung cancer drug market. Nature reviews. Drug discovery, 15(4): 229-230. https://doi.org/10.1038/nrd.2016.42
Niida H, Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis, 21(1): 3-9. https://doi.org/10.1093/mutage/gei063
Parmar K, Kochupurakkal B S, Lazaro J-B, Wang Z C, Palakurthi S, Kirschmeier P T, Yang C, Sambel L A, Färkkilä A, Reznichenko E, Reavis H D, Dunn C E, Zou L, Do K T, Konstantinopoulos P A, Matulonis U A, Liu J F, D'andrea A D, Shapiro G I (2019) The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(20): 6127-6140. https://doi.org/10.1158/1078-0432.CCR-19-0448
Patil M, Pabla N, Dong Z (2013) Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cellular and molecular life sciences : CMLS, 70(21): 4009-4021. https://doi.org/10.1007/s00018-013-1307-3
Politi K, Ayeni D, Lynch T (2015) The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer cell, 27(6): 751-753. https://doi.org/10.1016/j.ccell.2015.05.012
Rundle S, Bradbury A, Drew Y, Curtin N J (2017) Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers, 9(5). https://doi.org/10.3390/cancers9050041
Sanchez Y, Wong C, Thoma R S, Richman R, Wu Z, Piwnica-Worms H, Elledge S J (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science (New York, N.Y.), 277(5331): 1497-1501. https://doi.org/10.1126/science.277.5331.1497
Scully R, Panday A, Elango R, Willis N A (2019) DNA double-strand break repair-pathway choice in somatic mammalian cells. Nature reviews. Molecular cell biology, 20(11): 698-714. https://doi.org/10.1038/s41580-019-0152-0
Sen T, Tong P, Stewart C A, Cristea S, Valliani A, Shames D S, Redwood A B, Fan Y H, Li L, Glisson B S, Minna J D, Sage J, Gibbons D L, Piwnica-Worms H, Heymach J V, Wang J, Byers L A (2017) CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer research, 77(14): 3870-3884. https://doi.org/10.1158/0008-5472.CAN-16-3409
Smits V a J, Gillespie D A (2015) DNA damage control: regulation and functions of checkpoint kinase 1. The FEBS journal, 282(19): 3681-3692. https://doi.org/10.1111/febs.13387
Sung H, Ferlay J, Siegel R L, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3): 209-249. https://doi.org/10.3322/caac.21660
Teng J P, Yang Z Y, Zhu Y M, Ni D, Zhu Z J, Li X Q (2018) Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. European review for medical and pharmacological sciences, 22(12): 3819-3825. https://doi.org/10.26355/eurrev_201806_15266
Van Moorsel C J, Pinedo H M, Veerman G, Bergman A M, Kuiper C M, Vermorken J B, Van Der Vijgh W J, Peters G J (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. British Journal of Cancer, 80(7): 981-990. https://doi.org/10.1038/sj.bjc.6690452
Yang S-Y, Li Y, An G-S, Ni J-H, Jia H-T, Li S-Y (2018) DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine. International Journal of Molecular Sciences, 19(6). https://doi.org/10.3390/ijms19061587
Yasmeen A, Berdel W E, Serve H, Müller-Tidow C (2003) E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 3(5): 617-633.
Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, Yu W, Tong J, Zhang L, Lou Y, Qiu Y (2021) Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 133: 110996. https://doi.org/10.1016/j.biopha.2020.110996
Zhang Y, Hunter T (2014) Roles of Chk1 in cell biology and cancer therapy. International journal of cancer, 134(5): 1013-1023. https://doi.org/10.1002/ijc.28226
Zhao Z-M, Yost S E, Hutchinson K E, Li S M, Yuan Y-C, Noorbakhsh J, Liu Z, Warden C, Johnson R M, Wu X, Chuang J H, Yuan Y (2019) CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer, 19(1): 96. https://doi.org/10.1186/s12885-019-5290-4